Jay Olson
Stock Analyst at Oppenheimer
(3.55)
# 756
Out of 4,827 analysts
239
Total ratings
40.21%
Success rate
6.75%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMRX Immuneering | Maintains: Outperform | $25 → $21 | $1.15 | +1,726.09% | 2 | May 7, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Outperform | $6 | $0.60 | +893.87% | 6 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $50 → $42 | $14.28 | +194.12% | 4 | Mar 3, 2025 | |
| PRTA Prothena Corporation | Maintains: Outperform | $58 → $62 | $7.13 | +769.57% | 13 | Feb 7, 2025 | |
| EXEL Exelixis | Downgrades: Perform | $41 → $33 | $36.05 | -8.46% | 6 | Jan 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $60 → $40 | $7.84 | +410.20% | 9 | Jan 13, 2025 | |
| QTTB Q32 Bio | Maintains: Outperform | $80 → $20 | $1.56 | +1,182.05% | 2 | Dec 11, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $30 | $3.39 | +784.96% | 1 | Dec 6, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $17 → $20 | $3.01 | +564.45% | 2 | Dec 4, 2024 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $33 → $15 | $1.78 | +742.70% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $118.69 | +114.85% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $9 → $8 | $6.88 | +16.28% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $58.50 | +40.17% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $60 | $42.39 | +41.54% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $296.14 | +18.19% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $2.80 | +257.28% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $27.65 | +399.10% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.98 | +304.04% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $7.70 | +523.38% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $269.70 | +40.90% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $119.69 | +82.98% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $1.39 | +763.31% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.27 | +450.46% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.95 | +951.97% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $35.38 | +168.51% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $16.73 | +13.57% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.71 | +1,360.71% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $32.58 | +130.20% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.34 | +2,580.17% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 | $4.33 | +1,749.71% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $7.60 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $1.14 | +4,285.96% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $5.06 | +315.02% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.35 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $18.08 | +364.70% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.41 | - | 3 | Jul 11, 2017 |
Immuneering
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $1.15
Upside: +1,726.09%
Nektar Therapeutics
Mar 14, 2025
Upgrades: Outperform
Price Target: $6
Current: $0.60
Upside: +893.87%
Denali Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $14.28
Upside: +194.12%
Prothena Corporation
Feb 7, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $7.13
Upside: +769.57%
Exelixis
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $36.05
Upside: -8.46%
Intellia Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $7.84
Upside: +410.20%
Q32 Bio
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.56
Upside: +1,182.05%
Sagimet Biosciences
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $3.39
Upside: +784.96%
Terns Pharmaceuticals
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $3.01
Upside: +564.45%
Inovio Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $33 → $15
Current: $1.78
Upside: +742.70%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $118.69
Upside: +114.85%
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $6.88
Upside: +16.28%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $58.50
Upside: +40.17%
Oct 28, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $42.39
Upside: +41.54%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $296.14
Upside: +18.19%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $2.80
Upside: +257.28%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $27.65
Upside: +399.10%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.98
Upside: +304.04%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $7.70
Upside: +523.38%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $269.70
Upside: +40.90%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $119.69
Upside: +82.98%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $1.39
Upside: +763.31%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.27
Upside: +450.46%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.95
Upside: +951.97%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $35.38
Upside: +168.51%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $16.73
Upside: +13.57%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $1.71
Upside: +1,360.71%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $32.58
Upside: +130.20%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.34
Upside: +2,580.17%
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $4.33
Upside: +1,749.71%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $7.60
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $1.14
Upside: +4,285.96%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $5.06
Upside: +315.02%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.35
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $18.08
Upside: +364.70%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.41
Upside: -